'Biologic medicines' presentation slideshows

ASBM Biosimilars

ASBM Biosimilars. US Prescribers and Biosimilars Naming. Kevin Olson, CEO Industry Standard Research KevinO@ISRreports.com October, 2015. Table of contents. Page 3 Methodology 12 Drug Recording Practices 20 Product Naming Attitudes and Beliefs 32 Substitution Attitudes and Beliefs.

389 views • 38 slides

U.S. and European Physician Perspectives on Biosimilar Naming and Substitution

U.S. and European Physician Perspectives on Biosimilar Naming and Substitution. Michael S. Reilly, Esq. Executive Director, Alliance for Safe Biologic Medicines Presented at the Food and Drug Law Institute 57 th Annual Conference April 23, 2014 Washington, DC. ASBM.

264 views • 26 slides

Large scale evidence generation for the utilisation and safety of biologic medicines

Large scale evidence generation for the utilisation and safety of biologic medicines. Associate Professor Nicole Pratt Quality use of medicines and pharmacy research centre University of South Australia. overview.

248 views • 24 slides

PhAMA Position on Biosimilar Medicines

PhAMA Position on Biosimilar Medicines. Ms. Leah Goodman. Contents. An Overview - Biological Medicines and their Regulatory Framework. PhAMA Position and Recommendation on Biosimilars. Key Messages. An Overview - Biological Medicines and their Regulatory Framework.

197 views • 19 slides

Biologic Medicines

61 views • 5 slides